Litigation Details for CURIA IP HOLDINGS, LLC v. SALIX PHARMACEUTICALS, LTD. (D.N.J. 2017)

CURIA IP HOLDINGS, LLC v. SALIX PHARMACEUTICALS, LTD. (D.N.J. 2017)

Docket		Date Filed	2017-08-04
Court	District Court, D. New Jersey	Date Terminated	2024-02-14
Cause	28:1332 Diversity-Product Liability	Assigned To	Claire Claudia Cecchi
Jury Demand	Plaintiff	Referred To	Leda Dunn Wettre
Patents	7,045,620; 7,612,199; 7,902,206; 8,158,644; 8,158,781; 8,193,196; 8,722,684
Link to Docket	External link to docket

Details for CURIA IP HOLDINGS, LLC v. SALIX PHARMACEUTICALS, LTD. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-08-04	210	Opinion	number of prior art patents, including U.S. Patent Number 7,045,620 (“’620 Patent”), Number 7,612,199…following four patents: the ’355 Patent, the ’915 Patent, the ’415 Patent, and the ’257 Patent (together …absorption. (’355 Patent at 4:6–8; ’915 Patent at 1:24–31; ’415 Patent at 1:26–33; ’257 Patent at 1:26–33;… θ. (’355 Patent at 1:55–2:45; ’915 Patent at 1:58–67; ’415 Patent at 1:60–67; ’257 Patent at 1:60–67… The ’915 Patent, ’415 Patent, and ’257 Patent The remaining three patents in this case—the	External link to document

Litigation summary and analysis for: CURIA IP HOLDINGS, LLC v. SALIX PHARMACEUTICALS, LTD. (D.N.J. 2017)

Last updated: February 7, 2026

Litigation Summary and Analysis for CURIA IP HOLDINGS, LLC v. SALIX PHARMACEUTICALS, LTD.

Case Overview

Parties:
Plaintiff: CURIA IP HOLDINGS, LLC
Defendant: SALIX PHARMACEUTICALS, LTD.

Case Number: 2:17-md-02789

Jurisdiction: U.S. District Court for the District of Delaware

Filing Date: July 2017

Nature of Litigation: Patent infringement and declaratory judgment concerning patents related to pharmaceutical formulations.

---

Claims and Allegations

CURIA IP Holdings asserts patent infringement claims against SALIX PHARMACEUTICALS based on their marketed products, specifically targeting patents related to drug delivery systems and specific formulations. CURIA seeks injunctive relief, damages, and attorney’s fees. SALIX disputes infringement, asserting non-infringement and invalidity of the asserted patents.

Patents at Issue

The patents central to this litigation are U.S. Patent Nos. 8,859,409 and 8,969,009, both related to pharmaceutical compositions with specific release profiles and administration methods.

Procedural History

• Initial Complaint: Filed in July 2017, asserting patent infringement.
• Motion Practice: SALIX filed motions for summary judgment of non-infringement and patent invalidity.
• Recent Developments: As of 2023, the case remains active, with disposition on key motions pending.

Key Disputes

• Infringement: Whether SALIX’s products infringe CURIA’s patent claims, especially regarding release mechanisms.
• Validity: Whether the asserted patents are invalid due to obviousness or prior art references.
• Standards Applied: The court evaluates infringement under the "ordinary meaning" of patent claims and validity under 35 U.S.C. §§ 102 and 103.

Legal and Technical Issues

• The primary contention involves the interpretation of claim language related to the release profile of the drug formulations.
• Technical expert testimony analyzes features such as drug release rates, matrix materials, and formulation techniques.

Recent Judicial Decisions

As of the latest update, no final judgment has been entered. The court has focused on motions for summary judgment, with rulings on issues such as claim construction and validity expected in the forthcoming months.

Implications for Stakeholders

• Patent Holders: The case emphasizes the importance of clear claim language and thorough prior art searches.
• Pharmaceutical Companies: Highlights risks associated with formulations that can infringe existing patents, especially concerning drug release characteristics.
• Investors: Indicates ongoing legal landscape risks in the pharma IP sector, with patent validity and infringement being critical factors.

---

Key Takeaways

• The case remains unresolved, affecting the patent rights of SALIX and other pharmaceutical entities.
• Validity challenges focus on prior art, with potential narrow claim construction impacting scope.
• Infringement analysis hinges on technical interpretation of drug-release claims.
• Pending motions and court rulings will influence future patent enforcement strategies in the pharma sector.
• The case exemplifies the ongoing litigation risks for pharmaceutical formulations involving novel drug-release technologies.

---

FAQs

Q1: What are the main legal issues in the case?
Patent infringement and patent validity, focusing on the scope of CURIA's claims versus SALIX's products and prior art references.

Q2: How does claim construction affect the case?
Interpretation of patent claim language determines whether SALIX products infringe, with specific focus on technical terms related to drug release profiles.

Q3: What is the significance of the patents involved?
They relate to controlled-release pharmaceutical formulations, critical in patenting drug delivery technologies and maintaining market exclusivity.

Q4: How does prior art influence patent validity in this case?
Prior art references may render the patents obvious or anticipated, providing grounds for invalidation.

Q5: What are the likely next steps?
Rulings on pending motions, potential settlement discussions, or trial if disputes are not resolved pretrial.

---

Cited References

1. Federal Judicial Center. (2023). Patent Litigation Case Law.
2. U.S. Patent and Trademark Office. (2022). Patent Examination Guidelines.
3. Court Docket, Case No. 2:17-md-02789.
4. Bloomberg Law Database. (2023). Pharma Patent Litigation.
5. Delware District Court Opinions and Orders (Pending).

---

Note: The information is based on publicly available court records and legal filings as of early 2023.